Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: Evaluation of the pitfalls

Indian Journal of Pathology and Microbiology

Volumn 50, Issue 3, 2007, Pages 507-510

  Geramizadeh, Bita ^a   Boub, Roshanak ^a   Rahsaz, Marjan ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cholangiocarcinoma; HCC; HepPar1; MOC31

Indexed keywords

GLYCOPROTEIN;

ADENOCARCINOMA; ARTICLE; CELL DIFFERENTIATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; GALLBLADDER CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 34548249553     PISSN: 03774929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Lau SA, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma and metastatic adenocarcinoma. Human Pathol 2002; 33:1175-81.
2. Porcell Al, De Young BR, Proca DM, Frankel WL. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol 2000; 13(7): 773-8.
3. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma. An immunohistochemical comparison to CEA, CD10 and AFP. Am J Surg Pathol 2002; 26(8):978-88.
4. Ganjei P, Nadji M, albores-Saavedra J, Morales AR. Histologic markers in primary and metastatic tumors of the liver. Cancer 1988; 62:1994-8.
5. Ishak KG, Goodman ZD, Stockers JT. Hepatocellular Carcinoma. In: Atlas of tumor pathology, tumors of the liver and intrahepatic bile ducts. Third series. Fascicle 31: AFIP, 2001.
6. th edn. Mosby Co, 2004.
7. Leong ASY, Sormunen RT, Tsui WMS, Liew CT. Hepar 1 and selected antibodies in the immunohistological distinction of hepatocellular from cholangiocarcinoma, combined tumors and metastatic carcinoma. Histopathol 1998; 33:318-24.
8. Morrison C, Marsh W, Frankel WL. A comparison of CD10 to pCEA, MOC31, and Hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol 2002; 15(12):1279-87.
9. Fan Z, Van de Rijn M, Montgomery K, Rouse R. Hepar1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections.Mod Pathol 2003; 16(2):137-44.
10. Minervini MI, Demetris AJ, Lee RG, Carr BI, Madariaga J, Nalesnil MA. Utilization of hepatocyte specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997; 10(7):686-92.
11. Miatra A, Murakata LA, Albores-Saavedra J. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Am J Clin Pathol 2001; 115:686-94.
12. Sakamoto K, Monobe Y, Kouno M, Moriya T, Sasano H. Hepatoid adenocarcinoma of the gall bladder: Case report and review of the literature. Pathol Int 2004; 54(1):52-8.
13. Kashimoto T, Nagai Y, Kato K, Ozaki D, Ishikura H: Hepatoid adenocarcinoma: new clinicopathological entity and the hypothesis on carcinogenesis. Med Electron Microsc 2000; 33: 57-63.
14. Ishikura H, Kishimoto T, Andachi H, Kakuta Y, Yoshiki T: Gastrointestinal hepatoid adenocarcinoma: Venous permeation and mimicry of hepatocellular carcinoma, a report of four cases. Histopathology 1997; 31:47-54.
15. Ishikura H, Ishigura T, Entasu C,et al. Hepatoid adenocarcinoma of the renal pelvis producing AFP of hepatic type and bile pigment. Cancer 1991; 67:3051-6.